RG2133 (2',3',5'-tri-O-acetyluridine)
Phase 1Terminated 0 watching 0 views this week💤 Quiet
30
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Mitochondrial Diseases
Conditions
Mitochondrial Diseases
Trial Timeline
— → —
NCT ID
NCT00060515About RG2133 (2',3',5'-tri-O-acetyluridine)
RG2133 (2',3',5'-tri-O-acetyluridine) is a phase 1 stage product being developed by Repligen for Mitochondrial Diseases. The current trial status is terminated. This product is registered under clinical trial identifier NCT00060515. Target conditions include Mitochondrial Diseases.
Hype Score Breakdown
Clinical
10
Activity
5
Company
7
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00060515 | Phase 1 | Terminated |
Competing Products
13 competing products in Mitochondrial Diseases
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| REN001 | OnKure Therapeutics | Phase 1 | 25 |
| Mavodelpar + Placebo | OnKure Therapeutics | Phase 2 | 44 |
| REN001 | OnKure Therapeutics | Phase 2/3 | 57 |
| Bocidelpar + Placebo | Astellas Pharma | Phase 2 | 52 |
| Omaveloxolone capsules, 2.5 mg + omaveloxolone capsules, 5 mg + omaveloxolone capsules, 10 mg + Placebo capsules + omaveloxolone capsules, 20 mg + omaveloxolone capsules, 40 mg + omaveloxolone capsules, 80 mg + omaveloxolone capsules, 160 mg | AbbVie | Phase 2 | 52 |
| Cysteamine Bitartrate | Amgen | Phase 2 | 51 |
| Cysteamine Bitartrate | Amgen | Phase 2 | 51 |
| Vatiquinone | PTC Therapeutics | Phase 2/3 | 62 |
| EPI-743 | PTC Therapeutics | Pre-clinical | 20 |
| Vatiquinone | PTC Therapeutics | Pre-clinical | 20 |
| Vatiquinone | PTC Therapeutics | Phase 3 | 74 |
| Oral administration of 100 mg KH176 twice daily | Certara | Phase 2 | 47 |
| Sonlicromanol + Placebo | Certara | Phase 2 | 47 |